Here, we show that ablating the small peptide Apelin strikes one Achilles heel of current anti‐angiogenic therapy, reducing tumor angiogenesis and growth of the primary tumor while at the same time maintaining a better structured vasculature with higher pericyte coverage, impairing malignant progression, preventing hypoxia and distant metastasis. Here, APLN is linked to neoplasm.